Printer Friendly

Patent about-face.

A major biotechnology firm recently caused a stir by terminating its patent agreement with the universities holding the two major patents on gene-cloning techniques and products (SN: 5/18/85, p. 312). But now Cetus Corp. of Emeryville, Calif., has reversed its position. "We are delighted that they will resume the license," says Niels Reimers of Stanford University's Office of Technology Licensing. Robert Fildes, president of Cetus, says, "We wanted to resume our license as an indication of the high regard we have for the close collaboration in many fields between our two organizations." He adds that the company's business plans have changed since the earlier action, so "... the decision also fits in with our needs going forward."
COPYRIGHT 1985 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1985, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Cetus Corp. resumes patent license with Stanford University
Publication:Science News
Date:Sep 14, 1985
Words:118
Previous Article:New option in gene expression.
Next Article:Stop the music.
Topics:


Related Articles
Gene-splice patent showdown.
3 incumbents retain seats on school boards.
TRACK AND FIELD: FUTURE SITS AT 16 FEET USC SPOT AT STAKE FOR CRESPI SENIOR.
Lebanon, Syria, Fatah Al-Islam, Hariri & Iran Nuke Case - What's The Explosive Result?
Kudelka 101.
Invisible trail: analyzing the vortices in the wake of a bat.
This trick boosts cancer's spread.
A smart pill for seniors?

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters